KYMERA THERAPEUTICS INC (KYMR) Stock Price & Overview
NASDAQ:KYMR • US5015751044
The current stock price of KYMR is 81.9766 USD. Today KYMR is down by -4.8%. In the past month the price increased by 11.51%. In the past year, price increased by 161.81%.
KYMR Key Statistics
- Market Cap
- 6.693B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -3.68
- Dividend Yield
- N/A
KYMR Stock Performance
KYMR Stock Chart
KYMR Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to KYMR. When comparing the yearly performance of all stocks, KYMR is one of the better performing stocks in the market, outperforming 96.1% of all stocks.
KYMR Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to KYMR. While KYMR seems to be doing ok healthwise, there are quite some concerns on its profitability.
KYMR Earnings
On February 26, 2026 KYMR reported an EPS of -0.97 and a revenue of 2.87M. The company missed EPS expectations (-19.43% surprise) and missed revenue expectations (-81.3% surprise).
KYMR Forecast & Estimates
29 analysts have analysed KYMR and the average price target is 114.77 USD. This implies a price increase of 40.01% is expected in the next year compared to the current price of 81.9766.
For the next year, analysts expect an EPS growth of -2.7% and a revenue growth -19.39% for KYMR
KYMR Groups
Sector & Classification
KYMR Financial Highlights
Over the last trailing twelve months KYMR reported a non-GAAP Earnings per Share(EPS) of -3.68. The EPS decreased by -26.9% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -17.86% | ||
| ROE | -19.71% | ||
| Debt/Equity | 0 |
KYMR Ownership
KYMR Latest News, Press Relases and Analysis
KYMR Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.84 | 417.437B | ||
| AMGN | AMGEN INC | 16.15 | 204.229B | ||
| GILD | GILEAD SCIENCES INC | 16.24 | 183.894B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.65 | 121.25B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.48 | 83.255B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 48.28 | 43.24B | ||
| INSM | INSMED INC | N/A | 31.965B | ||
| NTRA | NATERA INC | N/A | 28.775B | ||
| BIIB | BIOGEN INC | 12.29 | 27.876B | ||
| MRNA | MODERNA INC | N/A | 22.581B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.28 | 21.486B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 20.053B | ||
| EXAS | EXACT SCIENCES CORP | 309.39 | 19.749B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About KYMR
Company Profile
Kymera Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of small molecule therapeutics that degrade disease-causing proteins. The company is headquartered in Watertown, Massachusetts and currently employs 238 full-time employees. The company went IPO on 2020-08-21. The firm is focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system with a primary focus on immunology. The firm's targeted protein degradation (TPD) platform, which is a small molecule therapeutic modality that engages the body’s natural cellular recycling system to selectively eliminate disease-causing proteins. Its immunology programs target STAT6, IRF5 and IRAK4, each of which addresses targets within validated pathways, providing the opportunity to treat a broad range of diseases. The company is developing KT-621 as part of its STAT6 program, which is being evaluated in a Phase I clinical trial in healthy volunteers. The company is developing KT-579, which is an investigational, first-in-class, oral degrader of IRF5, a genetically validated transcription factor and a master regulator of immunity.
Company Info
KYMERA THERAPEUTICS INC
500 North Beacon Street, 4Th Floor
Watertown MASSACHUSETTS 02139 US
CEO: Nello Mainolfi
Employees: 238
Phone: 13026587581
KYMERA THERAPEUTICS INC / KYMR FAQ
Can you describe the business of KYMERA THERAPEUTICS INC?
Kymera Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of small molecule therapeutics that degrade disease-causing proteins. The company is headquartered in Watertown, Massachusetts and currently employs 238 full-time employees. The company went IPO on 2020-08-21. The firm is focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system with a primary focus on immunology. The firm's targeted protein degradation (TPD) platform, which is a small molecule therapeutic modality that engages the body’s natural cellular recycling system to selectively eliminate disease-causing proteins. Its immunology programs target STAT6, IRF5 and IRAK4, each of which addresses targets within validated pathways, providing the opportunity to treat a broad range of diseases. The company is developing KT-621 as part of its STAT6 program, which is being evaluated in a Phase I clinical trial in healthy volunteers. The company is developing KT-579, which is an investigational, first-in-class, oral degrader of IRF5, a genetically validated transcription factor and a master regulator of immunity.
What is the stock price of KYMERA THERAPEUTICS INC today?
The current stock price of KYMR is 81.9766 USD. The price decreased by -4.8% in the last trading session.
What is the dividend status of KYMERA THERAPEUTICS INC?
KYMR does not pay a dividend.
What is the ChartMill rating of KYMERA THERAPEUTICS INC stock?
KYMR has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the valuation of KYMERA THERAPEUTICS INC (KYMR) based on its PE ratio?
KYMERA THERAPEUTICS INC (KYMR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.68).
Would investing in KYMERA THERAPEUTICS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on KYMR.
Can you provide the number of employees for KYMERA THERAPEUTICS INC?
KYMERA THERAPEUTICS INC (KYMR) currently has 238 employees.